EIM
FBRX icon

Essex Investment Management’s Forte Biosciences FBRX Stock Holding History

Essex Investment Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-222
Closed -$905K – 493
2019
Q1 		$905K Buy
+222
New +$858K 0.13% 213

Other funds holding FBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Essex Investment Management's FBRX Position: Q2 2019 in Review

Essex Investment Management sold out of Forte Biosciences (FBRX) in Q2 2019, closing a stake of 222 shares — an estimated $905K sold.

Essex Investment Management first reported a position in FBRX in Q1 2019 and held it in 1 quarter. The position peaked at $905K in Q1 2019. 74 funds tracked by Wall St. Rank hold FBRX as of Q2 2019.

  • Essex Investment Management reported no remaining Forte Biosciences position as of Q2 2019 after selling out during the quarter.
  • Essex Investment Management sold 222 Forte Biosciences shares in Q2 2019, an estimated $905K.
  • Essex Investment Management first reported a position in Forte Biosciences in Q1 2019 and held it in 1 quarter.
  • Essex Investment Management's Forte Biosciences position peaked at $905K in Q1 2019.
  • 74 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2019.

Based on Essex Investment Management's 13F filing for Q2 2019, filed 15 Aug 2019.